Revenue growth accelerated to 34.6% YoY in Q2 2026, with gross margin improving from 12.6% in Q1 2024 to 14.7% in Q1 2026, though operating margin remains negative at -2.9%.
Starling Oncology, Inc. (STLN) annual income statement — 7-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Sales/Revenue | 620.45M | 502.73M | 393.41M | 324.24M | 252.48M | 203M | 187.51M | 155.41M |
| Revenue Growth % | - | - | 21.33% | 28.42% | 24.37% | 8.26% | 20.66% | - |
| Cost of Goods Sold | 377.44M | 426.29M | 339.42M | 264.67M | 200.39M | 162.16M | 150.64M | 125.46M |
| COGS % of Revenue | - | 84.8% | 86.27% | 81.63% | 79.37% | 79.88% | 80.33% | 80.73% |
| Gross Profit | 73.25M | 76.44M | 54M | 59.57M | 52.09M | 40.85M | 36.88M | 29.94M |
| Gross Margin % | 11.81% | 15.2% | 13.73% | 18.37% | 20.63% | 20.12% | 19.67% | 19.27% |
| Gross Profit Growth % | - | - | -9.36% | 14.36% | 27.53% | 10.76% | 23.17% | - |
| Operating Expenses | 264.03M | 112.52M | 114.11M | 136.59M | 134.04M | 86.71M | 45.07M | 32.59M |
| OpEx % of Revenue | - | 22.38% | 29.01% | 42.13% | 53.09% | 42.71% | 24.04% | 20.97% |
| Selling, General & Admin | 118.33M | 105.57M | 0 | 0 | 0 | 0 | 41.9M | 29.64M |
| SG&A % of Revenue | - | 21% | - | - | - | - | 22.34% | 19.07% |
| Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 4M | 6.94M | 114.11M | 136.59M | 134.04M | 86.71M | 3.18M | 2.94M |
| Operating Income | -21.02M | -36.08M | -60.12M | -77.02M | -81.95M | -45.86M | -8.2M | -2.64M |
| Operating Margin % | -3.39% | -7.18% | -15.28% | -23.75% | -32.46% | -22.59% | -4.37% | -1.7% |
| Operating Income Growth % | - | - | 21.94% | 6.02% | -78.71% | -459.52% | -209.89% | - |
| EBITDA | -14.41M | -29.14M | -53.83M | -71.14M | -77.54M | -42.52M | -5.02M | 297.11K |
| EBITDA Margin % | -2.32% | -5.8% | -13.68% | -21.94% | -30.71% | -20.94% | -2.68% | 0.19% |
| EBITDA Growth % | - | - | 24.34% | 8.25% | -82.37% | -747.31% | -1788.91% | - |
| D&A (Non-Cash Add-back) | 6.61M | 6.94M | 6.29M | 5.87M | 4.41M | 3.34M | 3.18M | 2.94M |
| EBIT | -14.08M | -49.46M | -57.17M | -60.15M | -72.01M | -45.38M | -14.47M | -2.63M |
| Net Interest Income | -5.71M | -11.28M | -7.5M | -6.78M | -4.08M | -320K | -347K | -3.38K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 7.52M | 11.28M | 7.5M | 6.78M | 4.08M | 320K | 347K | 3.38K |
| Other Income/Expense | -14.52M | -24.65M | -4.54M | -6.09M | 81.86M | 34.26M | -6.62M | 6.63K |
| Pretax Income | -35.54M | -60.74M | -64.66M | -83.1M | -91K | -11.6M | -14.81M | -2.64M |
| Pretax Margin % | -5.73% | -12.08% | -16.44% | -25.63% | -0.04% | -5.71% | -7.9% | -1.7% |
| Income Tax | 0 | -131K | 0 | -36K | -243K | -671K | -492.82K | 1.38M |
| Effective Tax Rate % | 0% | 0.22% | 0% | 0.04% | 267.03% | 5.79% | 3.33% | -52.43% |
| Net Income | -35.54M | -60.61M | -64.66M | -83.07M | 152K | -10.93M | -14.32M | -4.02M |
| Net Margin % | -5.73% | -12.06% | -16.44% | -25.62% | 0.06% | -5.38% | -7.64% | -2.59% |
| Net Income Growth % | - | - | 22.16% | -54750% | 101.39% | 23.7% | -256.13% | - |
| Net Income (Continuing) | -35.54M | -60.61M | -64.66M | -83.07M | 152K | -10.93M | -14.32M | -4.02M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.03 | -0.54 | -0.71 | -0.92 | -0.21 | -0.16 | -0.24 | -0.06 |
| EPS Growth % | - | - | 22.83% | -338.1% | -31.25% | 33.33% | -284.62% | - |
| EPS (Basic) | - | -0.54 | -0.71 | -0.92 | 0.00 | -0.16 | -0.24 | -0.06 |
| Diluted Shares Outstanding | 1.05B | 92.39M | 75.04M | 73.75M | 80.61M | 66.23M | 59.12M | 64.45M |
| Basic Shares Outstanding | 1.05B | 92.39M | 75.04M | 73.75M | 72.79M | 66.23M | 59.12M | 64.45M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying STLN stock.
For fiscal year 2025, Starling Oncology, Inc. (STLN) reported total revenue of $502.7M. This represents a 223.5% increase compared to $155.4M in 2019.
Starling Oncology, Inc. (STLN) reported a net loss of $60.6M for the fiscal year ending 2025.
Starling Oncology, Inc. (STLN) reported an operating income of $-36.1M, resulting in an operating profit margin of -7.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Starling Oncology, Inc. (STLN) generated $76.4M in gross profit for the year, representing a gross profit margin of 15.2%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Persistent operating losses
Metrics are mathematically derived from official filings.
Revenue Momentum Accelerates Sharply
TOI's revenue surged 34.6% year-over-year to $161.3M in 2026Q2, accelerating from 21.5% growth in 2025Q2, according to the latest quarterly report.
The sequential acceleration from 21.5% to 34.6% suggests the company is scaling its oncology care network rapidly, likely through de novo clinic openings or acquisitions. However, the sustainability of this growth is uncertain as it outpaces the broader market, and investors should monitor whether volume or pricing is the primary driver.
Gross Margin Expansion Signals Pricing Power
Gross margin improved from 12.6% in 2024Q1 to 14.7% in 2026Q1, though it dipped to 14.7% in 2026Q1 from 16.0% in 2025Q4, per financial statements.
The upward trend in gross margin from 12.6% to 14.7% over two years indicates improving cost management or better payer contracts, but the recent sequential decline suggests volatility. This margin remains thin relative to peers, implying limited pricing power in a competitive reimbursement environment.
Operating Leverage Emerging as Losses Narrow
Operating loss improved from -$18.0M in 2024Q1 to -$4.6M in 2026Q2, with operating margin rising from -19.0% to -2.9%, based on reported quarterly data.
The operating margin improvement from -19.0% to -2.9% indicates that revenue growth is outpacing fixed cost increases, demonstrating positive operating leverage. However, the company still operates at a loss, and the path to profitability depends on sustaining this leverage while managing SG&A growth.
Net Losses Fluctuate with Non-Operating Items
Net income swung from -$19.9M in 2024Q1 to -$9.8M in 2026Q2, but EPS improved 46.7% year-over-year, as per the income statement.
The wide variance in net income relative to operating income suggests significant non-operating items, such as interest expense or one-time charges, are impacting the bottom line. Stock-based compensation of $2.8M in 2026Q2 adds to dilution, but the improving EPS trend indicates the company is reducing losses per share.
SG&A Discipline Drives Margin Recovery
SG&A as a percentage of revenue fell from 24.9% in 2024Q4 to 18.5% in 2026Q2, while COGS remained the dominant cost, per the latest filings.
The reduction in SG&A intensity from 24.9% to 18.5% of revenue indicates improved overhead efficiency, which is critical for a company with thin gross margins. However, COGS still consumes over 85% of revenue, leaving little room for error in cost control.
2025Q2 Marks Turning Point in Loss Trajectory
Operating loss peaked at -$18.0M in 2024Q1, then steadily improved to -$4.6M by 2026Q2, a 74% reduction, according to quarterly income statements.
The inflection began in 2025Q2 when revenue growth accelerated past 20% and operating margin improved from -9.5% to -9.4%, signaling that scale was starting to offset fixed costs. This trend has persisted, suggesting the company may be approaching breakeven, but the durability of this improvement depends on maintaining revenue growth.
What Could Invalidate the Base Case
Despite narrowing losses, TOI's gross margin remains thin and volatile, and the company has not yet achieved profitability, raising questions about the durability of its growth.
Short-sellers might argue that the revenue acceleration is not translating into sustainable profitability, as gross margins are still below 15% and operating losses persist. The reliance on SG&A cuts to drive margin improvement may not be repeatable, and any slowdown in revenue growth could expose the lack of underlying earnings power. Additionally, the high stock-based compensation suggests dilution risks that could pressure EPS further.